Prenatal alcohol exposure, biomarkers and fetal alcohol spectrum disorders

Paul R. Gard, Media Zanganeh, David J. Timson

Research output: Chapter in Book/Conference proceeding with ISSN or ISBNChapterResearchpeer-review

Abstract

Fetal Alcohol Spectrum Disorders (FASD) is the term used to describe neurobehavioral disorders associated with prenatal alcohol exposure ranging from the most severe Fetal alcohol syndrome (FAS) with facial dysmorphology, through partial Fetal alcohol syndrome (pFAS) to alcohol-related birth defects (ARBD). Many of the cognitive impairments associated with FASD are similar to those seen in Attention Deficit Hyperactivity Disorder (ADHD), Autistic Spectrum Disorders and other such conditions. There are considerable problems in diagnosing FASD and evidence of more than minimal exposure to ethanol during pregnancy is an important criterion. Information on the mother's alcohol consumption during pregnancy may not be available, or may be inaccurate. Furthermore, approximately half of children affected by FASD may not exhibit signs of CNS dysfunction until they are preschool or school-age when the child and the mother may have become separated. Early accurate differential diagnosis would enable the most effective treatments to be used. Ideally biomarkers would be identified which would enable confirmation of prenatal alcohol exposure. The use of meconium as an accessible fetal source of fatty acid ethyl esters (FAEEs), ethyl glucuronide (EtG) and ethyl sulfate (EtS) is frequently considered, but this is only applicable for the first few days of the neonate's life. The use of neonatal blood phosphatidylethanol (PEth) has also been discussed, but again the longevity of this biomarker is short. More recently results from animal studies of neonatal plasma microRNA biomarkers and changes to histone modifications have provided new opportunities, and DNA methylation has been suggested as a potential biomarker. Our own work suggests that prenatal alcohol exposure may induce long-lived changes in brain derived neurotrophic factor (BDNF) and brain aminopeptidase activity which may be reflected in changes in plasma or urine. In the light of the evidence that many fetuses are exposed to alcohol but do not exhibit any degree of FASD, this review will assess the evidence of reliability of emerging enduring markers of prenatal alcohol exposure and explore whether they correlate only with prenatal alcohol exposure or also with FASD.

Original languageEnglish
Title of host publicationFetal Alcohol Syndrome
Subtitle of host publicationRecognition, Differential Diagnosis and Long-Term Effects
PublisherNova Science Publishers Inc
Pages19-57
Number of pages39
ISBN (Electronic)9781536146035
ISBN (Print)9781536146028
Publication statusPublished - 4 Dec 2018

Fingerprint

Fetal Alcohol Spectrum Disorders
Biomarkers
Alcohols
Histone Code
Mothers
Newborn Animals
Pregnancy
Meconium
Aminopeptidases
Brain-Derived Neurotrophic Factor
DNA Methylation
Attention Deficit Disorder with Hyperactivity
Autistic Disorder
MicroRNAs
Alcohol Drinking
Esters
Fetus
Differential Diagnosis
Ethanol
Fatty Acids

Cite this

Gard, P. R., Zanganeh, M., & Timson, D. J. (2018). Prenatal alcohol exposure, biomarkers and fetal alcohol spectrum disorders. In Fetal Alcohol Syndrome: Recognition, Differential Diagnosis and Long-Term Effects (pp. 19-57). Nova Science Publishers Inc.
Gard, Paul R. ; Zanganeh, Media ; Timson, David J. / Prenatal alcohol exposure, biomarkers and fetal alcohol spectrum disorders. Fetal Alcohol Syndrome: Recognition, Differential Diagnosis and Long-Term Effects. Nova Science Publishers Inc, 2018. pp. 19-57
@inbook{40156f59873b4b9d827fd7bcfb23e0a7,
title = "Prenatal alcohol exposure, biomarkers and fetal alcohol spectrum disorders",
abstract = "Fetal Alcohol Spectrum Disorders (FASD) is the term used to describe neurobehavioral disorders associated with prenatal alcohol exposure ranging from the most severe Fetal alcohol syndrome (FAS) with facial dysmorphology, through partial Fetal alcohol syndrome (pFAS) to alcohol-related birth defects (ARBD). Many of the cognitive impairments associated with FASD are similar to those seen in Attention Deficit Hyperactivity Disorder (ADHD), Autistic Spectrum Disorders and other such conditions. There are considerable problems in diagnosing FASD and evidence of more than minimal exposure to ethanol during pregnancy is an important criterion. Information on the mother's alcohol consumption during pregnancy may not be available, or may be inaccurate. Furthermore, approximately half of children affected by FASD may not exhibit signs of CNS dysfunction until they are preschool or school-age when the child and the mother may have become separated. Early accurate differential diagnosis would enable the most effective treatments to be used. Ideally biomarkers would be identified which would enable confirmation of prenatal alcohol exposure. The use of meconium as an accessible fetal source of fatty acid ethyl esters (FAEEs), ethyl glucuronide (EtG) and ethyl sulfate (EtS) is frequently considered, but this is only applicable for the first few days of the neonate's life. The use of neonatal blood phosphatidylethanol (PEth) has also been discussed, but again the longevity of this biomarker is short. More recently results from animal studies of neonatal plasma microRNA biomarkers and changes to histone modifications have provided new opportunities, and DNA methylation has been suggested as a potential biomarker. Our own work suggests that prenatal alcohol exposure may induce long-lived changes in brain derived neurotrophic factor (BDNF) and brain aminopeptidase activity which may be reflected in changes in plasma or urine. In the light of the evidence that many fetuses are exposed to alcohol but do not exhibit any degree of FASD, this review will assess the evidence of reliability of emerging enduring markers of prenatal alcohol exposure and explore whether they correlate only with prenatal alcohol exposure or also with FASD.",
author = "Gard, {Paul R.} and Media Zanganeh and Timson, {David J.}",
year = "2018",
month = "12",
day = "4",
language = "English",
isbn = "9781536146028",
pages = "19--57",
booktitle = "Fetal Alcohol Syndrome",
publisher = "Nova Science Publishers Inc",

}

Gard, PR, Zanganeh, M & Timson, DJ 2018, Prenatal alcohol exposure, biomarkers and fetal alcohol spectrum disorders. in Fetal Alcohol Syndrome: Recognition, Differential Diagnosis and Long-Term Effects. Nova Science Publishers Inc, pp. 19-57.

Prenatal alcohol exposure, biomarkers and fetal alcohol spectrum disorders. / Gard, Paul R.; Zanganeh, Media; Timson, David J.

Fetal Alcohol Syndrome: Recognition, Differential Diagnosis and Long-Term Effects. Nova Science Publishers Inc, 2018. p. 19-57.

Research output: Chapter in Book/Conference proceeding with ISSN or ISBNChapterResearchpeer-review

TY - CHAP

T1 - Prenatal alcohol exposure, biomarkers and fetal alcohol spectrum disorders

AU - Gard, Paul R.

AU - Zanganeh, Media

AU - Timson, David J.

PY - 2018/12/4

Y1 - 2018/12/4

N2 - Fetal Alcohol Spectrum Disorders (FASD) is the term used to describe neurobehavioral disorders associated with prenatal alcohol exposure ranging from the most severe Fetal alcohol syndrome (FAS) with facial dysmorphology, through partial Fetal alcohol syndrome (pFAS) to alcohol-related birth defects (ARBD). Many of the cognitive impairments associated with FASD are similar to those seen in Attention Deficit Hyperactivity Disorder (ADHD), Autistic Spectrum Disorders and other such conditions. There are considerable problems in diagnosing FASD and evidence of more than minimal exposure to ethanol during pregnancy is an important criterion. Information on the mother's alcohol consumption during pregnancy may not be available, or may be inaccurate. Furthermore, approximately half of children affected by FASD may not exhibit signs of CNS dysfunction until they are preschool or school-age when the child and the mother may have become separated. Early accurate differential diagnosis would enable the most effective treatments to be used. Ideally biomarkers would be identified which would enable confirmation of prenatal alcohol exposure. The use of meconium as an accessible fetal source of fatty acid ethyl esters (FAEEs), ethyl glucuronide (EtG) and ethyl sulfate (EtS) is frequently considered, but this is only applicable for the first few days of the neonate's life. The use of neonatal blood phosphatidylethanol (PEth) has also been discussed, but again the longevity of this biomarker is short. More recently results from animal studies of neonatal plasma microRNA biomarkers and changes to histone modifications have provided new opportunities, and DNA methylation has been suggested as a potential biomarker. Our own work suggests that prenatal alcohol exposure may induce long-lived changes in brain derived neurotrophic factor (BDNF) and brain aminopeptidase activity which may be reflected in changes in plasma or urine. In the light of the evidence that many fetuses are exposed to alcohol but do not exhibit any degree of FASD, this review will assess the evidence of reliability of emerging enduring markers of prenatal alcohol exposure and explore whether they correlate only with prenatal alcohol exposure or also with FASD.

AB - Fetal Alcohol Spectrum Disorders (FASD) is the term used to describe neurobehavioral disorders associated with prenatal alcohol exposure ranging from the most severe Fetal alcohol syndrome (FAS) with facial dysmorphology, through partial Fetal alcohol syndrome (pFAS) to alcohol-related birth defects (ARBD). Many of the cognitive impairments associated with FASD are similar to those seen in Attention Deficit Hyperactivity Disorder (ADHD), Autistic Spectrum Disorders and other such conditions. There are considerable problems in diagnosing FASD and evidence of more than minimal exposure to ethanol during pregnancy is an important criterion. Information on the mother's alcohol consumption during pregnancy may not be available, or may be inaccurate. Furthermore, approximately half of children affected by FASD may not exhibit signs of CNS dysfunction until they are preschool or school-age when the child and the mother may have become separated. Early accurate differential diagnosis would enable the most effective treatments to be used. Ideally biomarkers would be identified which would enable confirmation of prenatal alcohol exposure. The use of meconium as an accessible fetal source of fatty acid ethyl esters (FAEEs), ethyl glucuronide (EtG) and ethyl sulfate (EtS) is frequently considered, but this is only applicable for the first few days of the neonate's life. The use of neonatal blood phosphatidylethanol (PEth) has also been discussed, but again the longevity of this biomarker is short. More recently results from animal studies of neonatal plasma microRNA biomarkers and changes to histone modifications have provided new opportunities, and DNA methylation has been suggested as a potential biomarker. Our own work suggests that prenatal alcohol exposure may induce long-lived changes in brain derived neurotrophic factor (BDNF) and brain aminopeptidase activity which may be reflected in changes in plasma or urine. In the light of the evidence that many fetuses are exposed to alcohol but do not exhibit any degree of FASD, this review will assess the evidence of reliability of emerging enduring markers of prenatal alcohol exposure and explore whether they correlate only with prenatal alcohol exposure or also with FASD.

UR - http://www.scopus.com/inward/record.url?scp=85061124089&partnerID=8YFLogxK

M3 - Chapter

SN - 9781536146028

SP - 19

EP - 57

BT - Fetal Alcohol Syndrome

PB - Nova Science Publishers Inc

ER -

Gard PR, Zanganeh M, Timson DJ. Prenatal alcohol exposure, biomarkers and fetal alcohol spectrum disorders. In Fetal Alcohol Syndrome: Recognition, Differential Diagnosis and Long-Term Effects. Nova Science Publishers Inc. 2018. p. 19-57